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” The beginning of knowledge is the 
discovery of something we do not 
understand.” 
Frank Herbert (1920-1986) 
  
 
  
  
Inflammation in the immature brain 
The role of Toll-like receptors  
Linnea Stridh 
Department of Physiology, Institute of Neuroscience and Physiology 
Sahlgrenska Academy at University of Gothenburg 
Göteborg, Sweden 
ABSTRACT 
Infection/inflammation and/or hypoxia-ischemia (HI) are major causes of perinatal 
brain injury. Toll-like receptors (TLRs), important components of innate immunity, 
have been shown to be involved in brain injury, both after infectious and 
endogenous, non-infectious, stimuli. The overall aim of this thesis was to study the 
expression of TLRs in the immature brain, choroid plexus and endothelial cells after 
inflammatory stimuli and/or HI, and to investigate the role of TLRs, their adaptor 
proteins MyD88 and TRIF in brain damaging processes after HI. TLR stimuli, HI or 
a combination of them both was performed on mice at postnatal day 9. Brain injury 
and inflammatory responses were evaluated with immunohistochemistry, RT-qPCR 
and cytokine analyses. All investigated TLRs were expressed under basal conditions 
in the neonatal brain and several of the receptors were regulated in the brain, choroid 
plexus and blood brain barrier after inflammatory stimuli and/or HI. Additionally, 
systemic stimulation of TLR 1/2 and TLR 4 decreased the expression of occludin, a 
tight junction protein, in the choroid plexus. TLR 2 was constitutively expressed in 
astrocytes in white matter and in neurons in the paraventricular nucleus and 
contributed to brain damage following HI. In contrast, MyD88 and TRIF did not 
appear to play a role in the injury process after HI alone. Both lipopolysaccharide 
(LPS), a TLR 4 ligand, and Poly I:C, a TLR 3 ligand, sensitized the brain to HI in 
wild type mice. This effect was blocked in MyD88 and TRIF deficient mice. Both 
Poly I:C and LPS increased the proinflammatory cytokine levels in the brain and this 
increase was blocked/reduced in the TRIF and MyD88 deficient animals. To 
conclude, TLRs are expressed under basal conditions and regulated during 
inflammation in the brain as well as in choroid plexus and blood brain barrier. In 
particular, we found that TLR 2 contributes to injury following HI, indicating that it 
has a function in sterile inflammation in the neonatal brain. Further, both MyD88 and 
TRIF play essential roles in LPS/Poly I:C-sensitized HI neonatal brain injury. These 
findings suggest that TLRs are important in both physiological and pathological 
processes in the immature brain and may provide novel targets for neuroprotective 
therapies in the future. 
Keywords: hypoxia-ischemia, immature brain, inflammation, innate immunity, Toll-like 
receptors 
ISBN: 978-91-628-8352-2  
  
SAMMANFATTNING PÅ SVENSKA 
Ungefär 2 av 1000 födda fullgångna barn riskerar att utveckla hjärnskada från 
händelser som sker före, under eller strax efter födseln. Dessutom är 
förekomsten av hjärnskada betydligt högre hos barn som föds för tidigt. 
Nedsatt syre- och blodtillförsel (hypoxisk ischemi; HI) och/eller infektion är 
bidragande orsaker till att hjärnan skadas och kan leda till neurologiska 
handikapp så som cerebral pares, inlärningssvårigheter och epilepsi. 
Identifiering av mekanismerna bakom skadans uppkomst och på så vis 
förbättrade behandlingsmöjligheter skulle innebära ett rikare liv för många 
barn.  
Infektioner i blodet eller HI kan leda till inflammation i hjärnan. 
Inflammationen uppkommer genom att kroppens immunförsvar aktiveras. 
Immunsystemet har två försvarslinjer, medfödd och förvärvad immunitet. Det 
medfödda immunförsvaret upptäcker angripande mikroorganismer i kroppen 
genom speciella mottagare, så kallade receptorer, på kroppens celler. När 
dessa receptorer upptäcker en mikroorganism, aktiveras det medfödda 
immunförsvaret och en inflammation uppstår för att på så sätt förstöra 
mikroorganismen. Toll-lika receptorer (TLR) är en viktig del av det 
medfödda immunförsvaret och de är specialiserade på att upptäcka specifika 
molekyler (antigen) från främst bakterier och virus. Man har även upptäckt 
att TLR kan reagera på kroppsegna molekyler som kommer från skadade 
celler och vävnad. Man har idag identifierat ett tiotal TLRs hos människa och 
mus. När TLR upptäcker antigen aktiveras en signaleringskaskad via två 
olika adaptorproteiner, MyD88 och TRIF. Detta leder till att inflammatoriska 
signalmolekyler bildas.  
Syftet med den här avhandlingen är att undersöka TLRs roll vid skada 
orsakad av infektion, HI eller en kombination av de båda i den omogna 
hjärnan. I försöken har en modell i neonatal mus använts för att framkalla en 
hjärnskada liknande den man ser hos nyfödda barn.  
Vi fann att TLR finns uttryckta i den omogna hjärnan och i hjärnans 
barriärer, och att deras genuttryck regleras vid en infektion eller efter HI. 
Efter infektion minskade dessutom genuttrycket för occludin, ett protein som 
har som uppgift att ”limma ihop” cellerna i barriären, vilket kan leda till en 
öppning av barriären. En öppen barriär kan leda till att inflammatoriska 
molekyler och celler i blodet lättare tar sig in i hjärnan och därmed orsakar 
inflammation.  
  
Vi fann också att TLR 2 bidrar till hjärnskada efter HI medan 
adaptorproteinerna MyD88 och TRIF inte påverkade skadestorleken efter HI. 
Vi upptäckte att aktivering av TLR 3 och TLR 4 ökade hjärnans känslighet 
för HI och mössen fick större hjärnskador. Möss som saknade genen för 
MyD88 eller TRIF var skyddade mot denna ökade känslighet. Vid 
stimulering av TLR 3 och TLR 4 ökade också nivåerna av inflammatoriska 
molekyler i hjärnan. Denna effekt uppstod inte i mössen som saknade 
MyD88 eller TRIF. 
Dessa fynd visar att TLRs finns i den omogna hjärnan och att de kan vara 
viktiga både vid friska och sjuka tillstånd. Dessutom visar vi att TLRs kan 
spela roll i hjärnans barriärer. Genom att förstå TLRs roll i den 
inflammatoriska processen som följer efter en hjärnskada kan vi på sikt 
komma närmare målet att hitta bättre behandlingsstrategier än de som finns 
idag.  
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1 INTRODUCTION 
The developing brain is vulnerable to many different factors before, during 
and after birth. Low levels of oxygen or nutrients and/or the presence of 
infections/inflammation, can result in fetal brain injury. The risk of 
developing perinatal brain injury is about 2 in 1000 live births in term infants 
and even higher in preterm infants [1-4].  
1.1 Perinatal brain injury  
Perinatal hypoxia-ischemia (HI) is a major cause of brain injury in the 
newborn and can result in a range of motor and neurodevelopmental 
disabilities, such as cerebral palsy, mental retardation, visual motor or visual 
perceptive dysfunction, and epilepsy [5-7]. HI can occur due to different 
reasons such as occlusion/compression of the umbilical cord or impairment 
of blood flow and gas exchange of the placenta before or during birth. The 
preterm infant, due to immaturity of cardiovascular and lung function, might 
also suffer from circulatory and respiratory problems after birth, which can 
lead to HI.  
Maternal or intrauterine infection/inflammation is thought to be another 
major contributing factor underlying perinatal brain damage [8]. Intrauterine 
infection/inflammation can manifest either as clinical chorioamnionitis or 
fetal inflammatory response syndrome, both of which can be life-threatening 
to the fetus, or as histological chorioamnionitis that may be clinically silent 
(reviewed in [9]). There is clear evidence that chorioamnionitis is a major 
risk factor for preterm birth [10] and intrauterine infections have been 
identified as a risk factor for developing cerebral palsy in both term and 
preterm infants [11-13]. Furthermore, maternal infection has been associated 
with the development of perinatal brain injury not only directly, but also 
indirectly by increasing the vulnerability of the brain to a secondary insult, 
such as hypoxia, hyperoxia, mechanical ventilation, or other infections [14-
17]. In term infants, birth asphyxia may be preceded by antenatal infections 
and the combined exposure to infection and asphyxia creates an additive 
effect and increases the risk of developing spastic cerebral palsy [18]. 
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The pattern and distribution of perinatal brain injury is dependent on the 
severity of the insult and the age at which it occurs [19]. The recognition that 
different regions of the brain have different susceptibility to injury at 
different maturational stages has led to the knowledge that particular cell 
types within the central nervous system (CNS) are selectively vulnerable to 
brain insults. If an ischemic insult occurs early in gestation and the baby is 
born prematurely, cerebral white matter injury is most frequently observed 
[5, 20, 21]. Further, at term age equivalent, several imaging studies have 
reported reduction in grey matter volume associated with white matter injury 
in infants born prematurely [22, 23]. In the term infant with ischemic brain 
injury, damage is often characterized by injury to deep grey matter and 
cerebral cortex [24]. 
1.2 Mechanisms of brain injury after hypoxia-
ischemia 
The development of brain injury after HI is not a single “event” but is rather a 
process that proceeds over time. Magnetic resonance imaging (MRI) studies 
show progression of lesion size over the first few days after injury [25] and 
animal studies show that after the HI insult, many neurons die over a period 
of days to weeks [26]. The injury process after HI can be divided into two 
parts consisting of the primary phase that starts during and/or immediately 
after the insult and secondary phase that starts hours after the primary insult 
and can continue for several days [27, 28].  
HI induces a reduction in the supply of oxygen and nutrients to the brain, 
which results in a shift from aerobic to anaerobic metabolism [29, 30]. 
Anaerobic metabolism is an energy-inefficient state resulting in: rapid 
depletion of high-energy phosphate reserves, including adenosine 
triphosphate (ATP), accumulation of lactic acid, and the inability to maintain 
cellular functions. This disrupts active transport processes, resulting in 
intracellular accumulation of sodium, calcium, and water and a membrane 
depolarization. The membrane depolarization then results in a release of 
excitatory neurotransmitters, specifically glutamate, from axon terminals. 
Glutamate binds to N-metyl-D-aspartate (NMDA)-, α-amino-3-hydroxy-5-
methylisoxazole-4-propionic acid (AMPA)-, and kainate receptors resulting 
in an influx of calcium and triggering a cascade of cellular events that 
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mediate cell death, including generation of reactive oxygen species (ROS) 
and nitric oxide (NO), and lipidperoxidation (reviewed in [27, 31-34]).  
If the primary insult is transient, cerebral perfusion is restored and oxygen 
and glucose levels, and intracellular pH is normalized [28, 35]. However in 
many cases, a secondary energy failure will occur within hours after the 
initial insult, leading to another wave of glutamate release, formation of ROS 
and NO, inflammatory reactions and apoptosis. 
1.2.1 Cell death 
The severity of the insult may determine the mode of cell death, with severe 
injury resulting in necrosis, and a milder insult resulting in apoptosis [36, 37], 
although there is a continuum between these modes of cell death [38]. 
Necrosis is a passive process of cell swelling, disrupted cytoplasmic 
organelles, loss of membrane integrity, eventually lysis of the cell, and 
activation of an inflammatory process. In contrast, apoptosis is an active 
process distinguished from necrosis by the presence of cell shrinkage, nuclear 
pyknosis, chromatin condensation, and genomic fragmentation. Apoptosis is 
also the mechanism for refining cell connections and pathways during brain 
development [39]. Studies have shown that apoptosis may play a prominent 
role in the evolution of HI injury in the neonatal brain and may be more 
important than necrosis after injury [40]. 
The two main apoptotic pathways are the intrinsic and the extrinsic pathway. 
Exitotoxicity (glutamate), oxidative stress, and other factors lead to injury of 
the mitochondrial membrane. The intrinsic pathway starts with 
permeabilisation of the mitochondrial membrane which leads to the release of 
several proapoptotic factors into the cytoplasm including cytochrome c, 
apoptosis-inducing factor (AIF), caspase-9, and endonuclease G [41]. Release 
of cytochrome c leads to the activation of caspase-9 and is followed by the 
conversion of procaspase-3 to active caspase-3 [26, 42]. Caspase-3 activation 
results in proteolysis of essential cellular proteins, including cytoskeletal 
proteins and kinases and can commit the cell to the morphological changes 
characteristic of apoptosis [43]. Activated caspase-3 has been shown in 
human postmortem brain tissue of full-term neonates with severe perinatal 
asphyxia [44]. 
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The extrinsic pathway is initiated by the activation of cell surface receptors 
responsive to inflammatory stimuli such as the tumor necrosis factor receptor 
superfamily (TNFRSF), where the Fas death receptor is one of the most 
studied TNFRSF members [45-47]. Activation of Fas involves caspase-8 and 
subsequently caspase-3 activation [47, 48]. HI has been found to activate Fas 
death receptor signaling in the neonatal brain [49]. 
1.3  Inflammation 
Inflammation is part of the biological response of vascular tissues to harmful 
stimuli, such as pathogens. Inflammation is characterized by the cardinal 
signs redness, heat, swelling, and pain and is a protective attempt by the 
organism to remove the injurious stimuli and to initiate the healing process. 
However, extensive, prolonged, or unregulated inflammation is highly 
detrimental and can cause more damage to the tissue than the initial 
inflammatory stimuli. The inflammatory process involves invasion of 
inflammatory cells, such as neutrophils and monocytes/macrophages, and the 
production of inflammatory mediators, such as cytokines, chemokines, and 
ROS. In addition to infection, trauma and HI can trigger an inflammatory 
response, a so-called “sterile inflammation”. This process is not fully 
understood but it has been shown that endogenous molecules from damaged 
cells and tissues can trigger an inflammatory response through interacting 
with receptors that normally detect microbial signals [50-52]. 
1.3.1 Inflammation in the brain 
For a long time the CNS was considered to be “immunologically privileged”; 
i.e. protected from the immune system due to the blood-brain-barrier (BBB), 
that restricts the access of inflammatory cells and molecules into the brain. 
However, it is becoming evident that leukocytes as well as cytokines and 
chemokines can cross the intact BBB. It is also known that the CNS can exert 
its own immune response, mainly through microglia and also to a lesser 
extent through astrocytes [53].  
The inflammatory response, in conjunction with excitotoxic (glutamate) and 
oxidative responses, is the major contributor to ischemic injury in the 
immature brain (Reviewed in [54]. After a HI injury, the generation of ROS 
and the accumulation of intracellular calcium in neurons and other brain 
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cells, leading to inflammatory cell activation and infiltration, trigger the 
immune response. Ischemic brain cells secrete inflammatory cytokines and 
chemokines causing upregulation of adhesion molecules in the cerebral 
vasculature and recruitment of peripheral leukocytes into the ischemic lesion. 
Once activated, inflammatory cells can release a variety of cytotoxic reagents 
such as cytokines, matrix metalloproteinases (MMPs), NO, and more ROS. 
This can all contribute to more cell damage as well as disruption of the BBB 
and extracellular matrix. Whether inflammation is good or bad in the brain 
after injury is still under debate. For example, inhibition of microglia have 
been found to both worsen [55] HI injury and protect [56] the brain against 
HI damages.  
1.3.2 Inflammatory mediators 
Neutrophils 
Neutrophils are one of the most important cell types of the innate immune 
system and their main function is to eliminate pathogens, which have invaded 
the tissue. Neutrophils are normally residing in the blood but in response to 
inflammatory mediators released from sites of injury/infection, activated 
neutrophils migrate into the tissue towards the site of injury. In the immature 
brain, accumulation of neutrophils have been demonstrated within the blood 
vessels and in the injured tissue at early time points (up to 24 h) after HI [57, 
58], and they can contribute to injury after HI as depletion of neutrophils was 
found protective [58, 59]. Neutrophils can enhance injury via several 
different mechanisms, including ROS production [60] and release of MMP-9 
[61], acting both from within the tissue and from the peripheral circulation. 
Microglia/macrophages 
Macrophages are another important cell type in innate immunity and are 
specialized for removal of foreign particles/bacteria, phagocytosis of 
apoptotic/damaged cells, pathogen recognition and clearance, and immune 
regulation. Macrophages are derived from monocytes in the blood, which 
then migrate out into different tissues of the body and differentiate into 
macrophages. Microglia are the resident macrophages in the brain and act as 
the first and main form of active immune defense in the CNS (reviewed in 
[62]). Activated microglia are found abundant in the brain following HI [57, 
63, 64], producing several mediators known to be injurious to the brain such 
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as proinflammatory cytokines [65, 66], NO [67], and MMPs [68], and they 
remain in the injured brain for weeks [69, 70]. While microglia contribute to 
the ischemic injury by secreting inflammatory mediators, they may also be 
involved in repair and neurogenesis [55, 71, 72]. 
Astrocytes 
Astrocytes play an important role in the brain where they perform many 
functions, including provision of nutrients to the nervous tissue, maintenance 
of extracellular ion balance, structure and maintenance of the BBB, and a role 
in the repair and scarring process of the brain after injury (reviewed in [73, 
74]).  Astrocytes can also play an immune modulating role in the brain [75]. 
In response to brain injury, astrocytes in the affected area will become 
activated. This activation process is called reactive gliosis and is triggered by 
cell death, inflammatory mediators and plasma proteins. Activated astrocytes 
migrate to the injured area and contribute to glial scars, which act as a barrier 
between the injured and the healthy tissue. In addition to restricting injury, 
activated astrocytes may also be involved in the inflammatory response after 
HI, since they have been shown to produce various inflammatory cytokines 
and chemokines in response to ischemia [76-79]. 
Cytokines 
Cytokines are small proteins (~25kDa) that are released by various cells in 
the body, usually in response to an activating stimulus, and induce responses 
through binding to specific receptors. They usually act in an autocrine or 
paracrine manner, thus affecting both the behavior of the releasing cells and 
cell-to-cell communication. Cytokines are upregulated in the brain after a 
variety of insults, including ischemic insults and inflammation. They are 
expressed in immune cells, but also produced endogenously in resident brain 
cells, including glia and neurons [66, 80], reviewed in [81].  
Cytokines are often divided into proinflammatory and anti-inflammatory 
cytokines, where interleukin (IL)-1β, tumor necrosis factor alpha (TNF-α), 
IL-6, and IL-10 are among the most studied ones in relation to inflammation 
in the brain. Both IL-1β and TNF-α can be released from activated 
macrophages or other glial cells at sites of infection [82-84]. TNF-α is 
upregulated in the adult brain after ischemia [85, 86] and in vitro experiments 
indicates that TNF-α induces apoptosis of oligodendrocytes [87, 88]. In vivo 
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intracerebral injection of TNF-α or IL-1β in newborn rats induced microglial 
activation, hemorrhage, and myelin damage [89].  
Recently, repeated systemic administration of IL-1β was shown to induce 
white matter damage in neonatal mice [90]. Following neonatal HI, IL-1β is 
increased and can be even further amplified by a simultaneous infection [66, 
91-93]. Genetic deletion of IL-1β was not protective against HI [94], whereas 
administration of IL-1ra, an inhibitor of IL-1β, protected the neonatal brain 
after HI [92, 93]. These differences may be due to the fact that IL-1β has 
different functions at various time points, which are all abrogated in the KO 
mice, while the inhibitor is operating only during the early phase of injury.  
IL-6 is mostly considered as a proinflammatory cytokine but the influence of 
IL-6 on the development of brain injury is more unclear. Although studies 
have consistently demonstrated elevated IL-6 levels in asphyxiated infants 
[95] and mice overexpressing IL-6 develop severe neurologic syndromes 
[96], others find that mice deficient in IL-6 develop more severe brain 
injuries [97].  
IL-10 is an anti-inflammatory cytokine which acts by inhibiting IL-1, TNF-α, 
and IL-6 [98-100]. Studies in adult animals and in cell cultures have shown 
that IL-10 has neuroprotective effects against glutamate-induced [101] or HI-
induced [102, 103] neuronal death and against lipopolysaccharide (LPS)- or 
interferon (IFN)-induced oligodendrocyte cell death [104]. Furthermore, IL-
10 counteracts acute effects of endotoxin on cerebral metabolism, 
microcirculation and oxygen tension during HI in the perinatal brain [105, 
106].  
Chemokines 
Chemokines are a family of small (8-14kDa) cytokines that have 
chemoattractant properties, inducing cells to migrate towards the source of 
the chemokine. Chemokines control cell migration, proliferation, 
differentiation and angiogenesis. In an inflammatory situation, chemokines 
act mainly as chemoattractants for leukocytes, recruiting inflammatory cells, 
such as monocytes and neutrophils from the blood to the site of injury. 
Chemokines are upregulated in the immature brain after HI [57].  
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In the adult brain, inhibition or deficiency of the chemokine monocyte 
chemoattractant protein-1 (MCP-1) is associated with reduced ischemic brain 
injury [107, 108], whereas overexpression is associated with increased injury 
[109]. In neonatal rodents, MCP-1 expression is increased following HI [110] 
and transient focal ischemia [70]. MCP-1 has also been found to be 
upregulated in the brain after inflammatory stimuli, such as LPS and virus 
associated double stranded RNA (dsRNA) [111, 112], and MCP-1 deficiency 
decreased brain inflammation after LPS [113]. IFN-γ induced protein 10 (IP-
10) has been found to be expressed by astrocytes, both in vivo and in vitro, 
after virus associated dsRNA stimuli [112, 114].  
1.3.3 Intracellular inflammatory signaling pathways 
Both cerebral ischemia and systemic infection results in regulation of gene 
expression in the brain, including rapid transcriptional activation of 
proinflammatory factors [115, 116].  
Nuclear factor κB 
Nuclear factor κB (NF-κB) is a protein complex that controls the 
transcription of DNA. NF-κB is found in almost all animal cell types and is 
involved in cellular responses to stimuli such as stress, cytokines, free 
radicals, and bacterial or viral antigens (reviewed in [117]). NF-κB is 
normally located in the cytoplasm as a heterodimer composed of p65 and p50 
subunits, bound to the endogenous inhibitor protein IκB. Phosphorylation of 
IκB by an upstream IκB kinase (IKK) releases NF-κB, allowing it to 
translocate into the nucleus and bind to functional κB-sites. NF-κB induces 
several important genes involved in inflammation, such as TNF-α, IL-6, IL-
1β and MCP-1 [118-122]. 
Mitogen-activated protein kinases 
The mitogen-activated protein kinase (MAPK) pathways transduce a large 
variety of external signals, leading to a wide range of cellular responses, 
including growth, differentiation, inflammation and apoptosis (reviewed in 
[123, 124]). The MAPK family is comprised of three subfamilies, 
extracellular signal-regulated kinase (ERK), p38 and c-jun N-terminal kinase 
(JNK). MAPKs are activated within the protein kinase cascades called 
“MAPK cascade”. Each one consists of three enzymes, MAPK, MAP kinase 
kinase (MKK) and MAP kinase kinase kinase (MKKK) that are activated in 
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series. Firstly, MKKK is activated by extracellular stimuli and 
phosphorylates MKK on its serine and threonine residues, and this MKK then 
activates a MAPK. Upon activation, transcription factors present in the 
cytoplasm or nucleus are phosphorylated and activated, leading to expression 
of target genes resulting in a biological response. ERK has been found to be 
generally protective in both adult and neonatal brain injury whereas p38 is 
best known as a transducer of stress-related signals, regulation of 
inflammatory genes production [123] and NF-κB recruitment to selected 
targets [125].  
1.4 Barriers of the brain 
The CNS is protected from the changeable milieu (e.g. ions, solutes, 
pathogens and proinflammatory cytokines) of the blood stream through the 
BBB and the blood-cerebrospinal fluid (CSF) barrier (BCSFB, see review 
[126-128]). The BBB and BCSFB act both as barrier systems to maintain 
CNS homeostasis, a necessity for proper neuronal function, as well as 
transport systems providing the brain with essential nutrients.  
The BBB is composed of endothelial cells, pericytes, basal lamina, and 
astrocytes (figure 1A) [129]. The BBB results from specialized properties of 
the endothelial cells, their intercellular junctions, and a relative lack of 
vesicular transport. The BCSFB consists of a single layer of epithelial cells in 
the choroid plexus that overlay an extensive network of fenestrated 
capillaries (figure 1B). Besides its barrier function, epithelial cells in choroid 
plexus produce and secrete CSF.  
Both BBB and BCSFB form physical barriers by a network of tight junctions 
between adjacent barrier forming cells (figure 1C, reviewed in [130]). The 
tight junctions are the key functional components of the CNS barriers and 
they limit the intercellular diffusion of substances such as hydrophilic 
molecules. Under pathological circumstances, such as inflammation or HI, 
tight junctions in the BBB seem to be readily modified and dysfunction of the 
BBB is typically followed by an increased permeability of the barrier 
allowing diffusion of water, proteins and solutes, leading to perivascular 
edema (reviewed in [131]).  
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Figure 1. Barriers of the brain. Schematic drawing of the blood-brain barrier(BBB, 
A) and choroid plexus (B). The BBB is composed of endothelial cells, pericytes and 
astrocytes. Barrier properties are formed by tight junctions between the endothelial 
cells (C). Choroid plexus consists of a single layer of epithelial cells overlaying an 
extensive network of fenestrated capillaries. The blood-CSF barrier is formed by 
tight junctions between the epithelial cells. Besides its barrier function, epithelial 
cells in choroid plexus produce and secrete CSF. 
 
1.4.1 Brain injury and barriers of the brain 
Disturbance of the brain barrier systems due to inflammation has been 
implicated as one of the leading causes in the pathology of several 
neurological diseases both in the young and the ageing brain [132-134]. 
Studies have shown that at the time of myelination, systemic inflammation 
results in increased BBB permeability to plasma proteins, specifically in 
white matter tracts, with a reduced amount of myelin as a result [134, 135].  
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In connection to inflammatory stimuli, LPS treated mice exhibited a broken 
basal lamina and pericyte detachment from the basal lamina at 6-24 h after 
LPS injection. This was correlated with increased microglial activation and 
increased cerebrovascular permeability [136]. In the choroid plexus, LPS 
induced an acute phase response with upregulation of genes involved in 
immune-mediated cascades and down-regulation of genes involved in 
maintenance of the barrier function [137-139].  
HI also affects the CNS barriers [68, 140]. After HI, opening of the BBB 
occurs shortly after the insult and MMP-9 contributes to this change [68]. In 
a rodent model, choroid plexus shows a selective vulnerability to ischemia 
and BCSFB disruption seems to occur before damage to the BBB [141].  
1.5 Toll-like receptors 
The immune defense of the body can be divided into innate and adaptive 
immunity, where the innate immune response is the first line of defense 
against microbial infections. The targets of innate immune recognition are the 
conserved molecular patterns of microorganisms, also called pathogen-
associated molecular patterns (PAMPs). Toll-like receptors (TLRs) play a 
key role in the innate immune system by recognizing a wide variety of 
PAMPs, such as peptidoglycan, LPS, bacterial DNA and dsRNA (for reviews 
see [142-144]). In addition to their role in pathogen detection and defense, 
TLRs act as sentinels of tissue damage and mediate inflammatory responses 
to aseptic tissue injury. Host-endogenous molecules associated with damaged 
cells and tissues, such as heat shock proteins, high mobility group box 1 
protein, and RNA, have been shown to activate TLRs [50-52]. 
1.5.1 Toll-like receptor signaling  
The TLR family consists of 13 members and TLR 1-9 are expressed in both 
mice and humans. They can be classified into two groups based on 
subcellular localization. The first group includes TLR 1, 2, 4, 5, and 6, which 
are all present at the plasma membrane [145]. The second group includes 
TLR 3, 7, 8, and 9, which localize to intracellular compartments such as 
endosomes and they sense in particular viral and bacterial nucleic acids. Viral 
particles are endocytosed and degraded in late endosomes or lysosomes, and  
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Figure 2. TLR signaling pathway. For details see text. 
this degradation causes the release of viral DNA and RNA, which then can 
come in contact with the TLRs.  
The key signaling domain involved in TLR signaling is the Toll-IL-1 
receptor resistance (TIR) domain (figure 2). All TLRs have this TIR domain 
and they signal via the recruitment of various TIR domain-containing adaptor 
proteins [143]. Upon activation, each TLR family member, except TLR 3, 
signals through the myeloid differentiation primary response protein 88 
(MyD88)- dependent pathway (reviewed in [146-148]).  
MyD88 is an adaptor protein, which upon recruitment to the activated 
receptor initiates a signaling cascade leading to activation of different 
transcription factors, e.g. NF-κB and activator protein 1 (AP1), and the 
generation of proinflammatory cytokines such as IL-6 and TNF-α. TLR 3 
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signals through the MyD88-independent pathway, initiated by the TIR 
domain-containing adaptor inducing interferon beta (TRIF) adaptor molecule. 
Recruitment of TRIF leads to the activation of the transcription factor 
interferon regulatory factor (IRF)-3 and -7 and the generation of antiviral 
molecules such as IFN-β. However, reports show that TRIF signaling also 
induces NF-κB-dependent transcription, partially through interaction with 
receptor-interacting protein 1 (RIP 1) kinase [149, 150]. RIP 1 also links 
TRIF to the apoptotic cascade, via Fas associated protein with death domain 
(FADD) and caspase-8 [151]. TLR 4 uses both MyD88 and TRIF. 
MyDD adapter-like (MAL) protein is a bridging protein, used by TLR 4 (and 
to a lesser extent by TLR 2), and is involved in recruitment of MyD88. This 
provides an extra control on TLR 4 signaling, because MAL is subject to 
multiple regulatory mechanisms. The fourth adaptor protein, TRIF-related 
adaptor molecule (TRAM), is used only by TLR 4 and is needed to recruit 
TRIF. Again, this provides an extra control of TLR 4 signaling, because 
TRAM is regulated by phosphorylation of protein kinase C ε [152]. The fifth 
and final adaptor is sterile alpha and TIR motif containing protein (SARM), 
which has been shown to inhibit signaling by TRIF and thereby limiting the 
IRF 3 pathway that is activated by TLR 3 and 4 [153]. 
1.5.2 TLRs and brain injury 
TLRs are constitutively expressed in the adult brain [154, 155], where they 
are widely expressed in different cell types (reviewed in [156]).  Not much is 
known about the direct role of TLRs in neonatal brain injury in humans but 
emerging data suggest a role for TLRs in preterm birth. Fetal membranes in 
the human placenta express TLRs, and the expression of TLR 2 and TLR 4 is 
increased in preterm delivery with histological chorionamnionitis [157-159]. 
Several studies have also shown an association between TLR polymorphisms 
and preterm birth [160, 161].  
In animal models, it has been shown that LPS, a TLR 4 ligand, injected 
directly into the brain induces white matter injury [162, 163]. Also systemic 
exposure to LPS can cause cerebral white matter injury in a variety of animal 
models [164-168]. Additionally, systemic administration of LPS sensitizes 
both the immature and the adult brain to a subsequent HI insult [169-173]. 
Stimulation of TLR 2 has been found to impair neonatal mouse brain 
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development [174] and to be involved in neurodegeneration induced by 
group B streptococci [175].  
As mentioned above, host-endogenous molecules associated with injury, e.g. 
heat shock proteins and RNA from necrotic cells can act as ligands to TLRs. 
This suggests that TLRs may be initiating some of the damaging 
inflammatory response to ischemic injury and there is increasing evidence 
that TLRs do play a role in ischemic damage. In adult studies, TLR 4 is 
found to be upregulated after ischemia reperfusion [176] and mice lacking 
TLR 2 or TLR 4 are less susceptible to transient focal cerebral 
ischemia/reperfusion damage [177, 178]. While reports suggest that TLR 2 
and 4 are important for stroke-like injury, much less is known about the role 
of the TLR adaptor proteins in brain injury. In the adult, neither disruption of 
MyD88 nor TRIF signaling protects against cerebral ischemia alone [179, 
180]. On the other hand, contradictive reports show that stimulation of the 
TRIF pathway either is neuroprotective by reprogramming the response of 
the adult brain to stroke [181] or exacerbates chronic neurodegeneration 
[182]. In the immature brain, neither TLR 4 nor MyD88 contribute to 
neonatal HI brain damage, without LPS [156]. The role of TRIF in neonatal 
brain injury is unknown. 
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2 AIM 
TLRs have been shown to be involved in brain injury, both after infectious 
and endogenous, non-infectious, stimuli. Most previous studies have been 
performed in the adult brain and knowledge about the role of TLRs in the 
immature brain is lacking. The overall aim of this thesis was to study the 
expression of TLRs in the immature CNS, its downstream intracellular 
signaling pathways, and brain injury outcomes after inflammatory stimuli 
with different TLR ligands and/or HI. 
 
Specific aims were: 
 To investigate the expression and regulation of TLRs in the brain, 
choroid plexus and microvessel endothelial cells after HI and 
inflammatory stimuli. 
 
 To investigate the role of the adaptor protein MyD88 in LPS-
sensitized neonatal HI brain injury. 
 
 To investigate the role of TRIF-dependent mechanisms in neonatal 
HI brain injury.  
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3 MATERIALS AND METHODS 
The material and methods used in this thesis are thoroughly described in the 
individual papers. A general description of material and methods with 
comments are presented below. 
3.1 Animals 
All animals were housed at Experimental Biomedicine, Sahlgrenska 
Academy, University of Gothenburg, Sweden. Mice were kept in a 12 h 
light-dark cycle with free access to food and water. All animal experiments 
were approved by the Animal Ethical Committee of Gothenburg (No. 314-05, 
277-07, and 374-09). Several different genetically modified mouse strains 
were used: C57BL/6J wild type (WT) mice were bought from Charles River 
(Germany) (I, IV), TLR 1 knock out (KO) mice were purchased from 
Oriental BioService, Inc (Tokyo, Japan) (I), TLR 2 KO mice (B6.129-
Tlr2tm1Kir/J) (I) and TRIF KO mice (C57BL/6J-Ticam1Lps2/J) (III) were 
bought from the Jackson Laboratory (USA), MyD88 KO mice were a kind 
gift from Kristina Eriksson (Department of Rheumatology and Inflammation 
Research, University of Gothenburg, Sweden). The MyD88 KO mice were 
originally from Dr Kawai, Department of Biochemistry, Hyogo College of 
Medicine, Japan (II). 
3.1.1 Breeding and genotyping (paper I-III) 
In general mice were bred to obtain WT, KO and heterozygote littermates 
(paper I-III). Mice were genotyped with different protocols depending on 
genotype. The genotype of MyD88 KO mice was determined by PCR of 
genomic DNA obtained from mouse tails, as previously described [183]. The 
WT allele was detected using the forward primer (5’-
TGGCATGCCTCCATCATAGTTAACC-3’) and the reverse primer (5’-
GTCAGAAACAACCACCACCATGC-3’), and the mutant allele detected 
using the forward primer (5’-TGGCATGCCTCCATCATAGTTAACC-3’) 
and the reverse primer (5’-ATCGCCTTCTATCGCCTTCTTGACG-3’). The 
PCR products were run on an agarose gel and WT mice were identified by a 
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single 550-bp band, MyD88 KO mice by the presence of a single 650-bp 
DNA band, and HET mice were identified by the presence of both bands.  
 
The genotype of TRIF KO mice was determined by reverse transcription-
quantitative PCR (RT-qPCR) of genomic DNA. Genotypes were detected 
through melting curve based genotyping. Primers used for the amplification 
step were: forward (5’-CCAATCCTTTCCATCAGCCT-3’) and reverse (5’-
CACTCTGGAGTCTAAGAAG-3’) (Tib Molbiol, Germany). For melting 
curve analysis following probes were used: (5’-
CACATGTGGGGCCACACAGGGG-FL) and (5’-LC640-
CCAGTCATCTGATGACAAGACTGAG-PH) (Tib Molbiol). The 
amplification protocol comprised an initial 5 min denaturation at 95°C, 
followed by 40 cycles of denaturation for 30 sec at 95°C and 
annealing/extension for 30 sec at 55°C followed by 1 min at 72°C and 
thereafter a melting curve analysis consisted of 1 min denaturation at 95°C 
followed by 3 min at 45°C and an increase of temperature to 95°C with a rate 
of 0.11°C/s on a LightCycler 480 (Roche). WT mice were identified with a 
melting temperature of 65-66°C, TRIF KO mice with a melting temperature 
of 59-60°C and heterozygotes were identified by the presence of both melting 
temperatures.  
 
Comment: In an attempt to minimize the number of animals used, TLR 1, 2 
and TRIF KO mice were bred to obtain WT or KO litters. TLR 1 and TLR 2 
mice were bred to obtain KO litters all through the experiment and they were 
therefore not genotyped for each experiment. To minimize variations due to 
external factors, the different genotypes (WT and KO) were run in the HI 
chamber at the same time when possible. MyD88 KO animals were crossed 
with WT to produce heterozygotes, which were bred further to produce 
littermate animals with mixed genotypes including MyD88 homozygous 
(KO), heterozygote, and WT mice. 
 
3.2 Hypoxic-ischemic brain injury model (paper 
I-III) 
At postnatal day (PND) 9, mice were anesthetized with isoflurane (3.0% for 
induction and 1.0-1.5% for maintenance) in a mixture of nitrous oxide and 
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oxygen (1:1). Through a small incision, the left common carotid artery was 
permanently ligated with prolene sutures and the incision was then closed 
again, (the whole procedure was less than 5 min). Mice were returned to the 
cage and allowed to recover for 1 h and then placed in an incubator circulated 
with a humidified gas mixture (10.00 ± 0.01% oxygen in nitrogen) at 36°C 
for 50 min. After hypoxia, the pups were returned to their dam until sacrifice. 
 
A combined model of infection and HI was used in paper II and III, where 
LPS (0.3 mg/kg, i.p. or polyinosinic-polycytidylic acid (Poly I:C, 10 mg/kg, 
i.p.) was administered to the animal 14 h prior to the HI insult. 
 
Comment: The Rice-Vannucci HI model used in this thesis is one of the most 
commonly used experimental models used to study perinatal HI brain injury 
[30]. Following HI, damage is restricted to the cerebral hemisphere ipsilateral 
to the common carotid artery occlusion. Injury is associated with infarction in 
the middle cerebral artery territory, including subcortical and periventricular 
white matter, striatum/thalamus, hippocampus, and cerebral cortex [30, 184] 
and the degree of damage is dependent on the duration of the systemic 
hypoxia [68]. The peak in brain growth occurs at around P7 in the rat, which 
occurs around term in humans [185]. However, with respect to cortical 
maturity [186], the presence of a periventricular germinal matrix, 
development of BBB, synapse formation (reviewed in [187]), and maturity of 
oligodendrocytes [188], the PND 7-9 rodent is slightly more immature than 
the term human fetus. Thus brain maturation in PND 8-PND 9 mice, used in 
the present thesis, is mostly characteristic of near term human brain 
development. 
3.3 Drug administration (paper II-IV) 
Pam3CSK4 (Pam, InvivoGen) 5mg/kg (IV), Poly I:C (InvivoGen) 5 mg/kg 
(III) and 10 mg/kg (III, IV),  or LPS (O55:B5; Sigma-Aldrich or ultrapure, 
#423, List biological laboratories, Inc.) 0.3 mg/kg (II, IV) was administered 
intraperitoneally (i.p.) to mice on PND 8.  
 
Comment: Pam is a synthetic lipopeptide that mimics the acylated amino 
terminus of bacterial lipoproteins and induces NF-κB activation through TLR 
1/2 activation. The dose given was chosen from previous studies where we 
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have shown that TLR 1/2 signaling pathway stimulation/activation impairs 
immature brain development [174]. Poly I:C is a synthetic analog of dsRNA, 
a molecular pattern associated with viral infection. Both natural and synthetic 
dsRNA is known to induce type I IFNs through activation of TLR 3. The 
Poly I:C dose given was chosen through a dose-response experiment where 
the maximum IFN-β response was measured by RT-qPCR (III). LPS is a 
constituent of the cell wall of gram negative bacteria and works as a ligand to 
TLR 4. LPS is commonly used experimentally to simulate infection and the 
dose given in this thesis has previously been shown to affect the 
inflammatory response in the brain and sensitize the immature brain to HI 
injury [116, 169].  
3.4 Tissue preparation 
For immunohistochemical staining, animals were deeply anesthetized and 
intracardially perfused with saline and 5% buffered formaldehyde (Histofix; 
Histolab). Brains were rapidly removed and immersion fixed in 5% 
formaldehyde for 24h. Brains were kept in a 30% sucrose solution until they 
were cut or put through dehydration with graded ethanol and xylene/ X-tra 
solv® (Medite,Germany) and embedded in paraffin. Coronal sectioning (25 
μm/section) was performed on a sliding microtome (Leica SM2000R, Leica 
Microsystems, Sweden), and sections were stored in tissue cryoprotectant 
solution (25% ethylene glycol, 25% glycerol and 0.1 M phosphate buffer) at -
20°C (I). Paraffin embedded brains were cut coronally (10 μm/section) on a 
rotating microtome (Leica RM2165, Leica Microsystems, Sweden) (I,II,III). 
 
For messenger RNA (mRNA) analysis, animals were deeply anesthetized and 
intracardially perfused with saline. Brains were rapidly dissected out; snap 
frozen and stored at -80°C until analysis. Brain tissue was homogenized with 
Qiasol lysis reagent homogenizer (Qiagen, Sweden) and total RNA was 
extracted using RNeasy Lipid Tissue Mini Kit (Qiagen, Sweden) according 
to the manufacturer’s instructions. RNA was measured in a 
spectrophotometer at 260-nm absorbance. (I,III,IV) 
 
For enzyme-linked immunosorbent assay (ELISA), brains were rapidly 
dissected on ice, homogenized by sonication in ice-cold isolation buffer 
consisting of protease inhibitor mixture (Complete Mini) and 10% FCS 
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(Perbio; HyClone) in phosphate buffered saline (PBS), and centrifuged twice 
at 5,000 x g for 5 min and twice at 10,000 x g for 10 min; the supernatant was 
collected and stored at -80°C until use (II). 
3.5 Immunohistochemistry 
For paraffin embedded sections (I-III), antigen recovery was performed by 
boiling the sections in 10 mM sodium citrate buffer (pH 6.0) for 10 min. 
Nonspecific binding was blocked for 30 min with 4% horse or goat serum 
(depending on the species used to raise the secondary antibody) in PBS. 
Sections were incubated in primary antibody at 4°C overnight, followed by 
the appropriate secondary antibody (biotinylated or fluorescent) for 60 min at 
room temperature. For biotinylated antibodies, visualization was performed 
using Vectastain ABC Elite (Vector Laboratories) with 0.5 mg/ml 3,3- 
diaminobenzidine enhanced with 15 mg/ml ammonium nickel sulfate, 2 
mg/ml β-D glucose, 0.4 mg/ml ammonium chloride, and 0.01 mg/ml β-
glucose oxidase (all from Sigma-Aldrich). Sections were analyzed on a 
Nikon Optiphot-2 microscope equipped with an AVT dolphin F145B camera 
(Allied Vision Technologies).  
 
Free floating sections (I) were treated with 0.6% H2O2 in Tris-buffered saline 
(TBS; 0.15 M NaCl and 0.1 M Tris-HCl, pH 7.5) for 30 min to block 
endogenous peroxidase activity. Nonspecific binding was blocked for 30 min 
in blocking solution (3% goat serum and 0.1% Triton-X 100 in TBS) and the 
sections were incubated with primary antibody in blocking solution at 4°C 
for 48 h, followed by the appropriate secondary antibody for 60 min at room 
temperature. Visualization was performed as described above. Sections were 
analyzed under an Olympus BX60 fluorescence microscope equipped with an 
Olympus DP50 cooled digital camera. Fluorescent staining was captured with 
a Leica TCS SP2 confocal system (Leica, Heidelberg, Germany) with 
channel settings appropriate to the fluorophores present. Sequentially 
scanned, grey scale Z-stacks were pseudocolored and processed in ImageJ 
(version 1.42u; National Institutes of Health, Bethesda, MD, 
http://rsb.info.nih.gov/ij) before final processing in Adobe Photoshop 
(version 11.0.2; Adobe Systems Inc., San Jose, CA). 
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Table 1. Antibodies used in immunohistochemistry 
Antibody Dilution Company, product 
number 
Paper 
HuC/D  1:500 Molecular Probes, 
A21271 
I 
GFAP  1:1000 Covance,  
PCK-591P 
I 
Iba-1  1:1000 Abcam, 
ab5076 
I 
MAP-2 1:1000 Sigma-Aldrich, 
clone HM-2 
I-III 
MBP 1:10 000 Covance, 
SMI-94R 
II-III 
Neu N 1:1000 Chemicon International, 
MAB377 
I 
NeuN- Alexa 488 1:1000 Chemicon International, 
MAB377X 
I 
Olig2 1:1000 R&Dsystems, 
AF2418 
I 
TLR 1 1:500 Imgenex, 
IMG-5012 
I 
TLR 2 1:100 Imgenex, 
IMG-526 
I 
 
Comment: Immunohistochemistry (IHC) is a sensitive method for the 
localization of antigens in tissue sections. There are a few things to consider 
when performing IHC. Antigen retrieval is important since many antigens 
can become ”hidden” when processing the tissue. The specificity of the 
antibodies is crucial, as non-specific binding leads to false positive results. 
One way to check for non-specific binding of secondary antibodies is to 
incubate sections with secondary antibody without the addition of primary 
antibody. Incubation of the primary antibody with its recombinant antigen 
prior to staining can also be used to detect non-specific staining. In this thesis 
the specificity was tested by incubating sections with secondary antibody 
only. 
3.6 Neuropathological analysis 
For brain injury evaluation, brains were embedded in paraffin and cut into 10 
µm frontal sections. For evaluation of grey matter injury, every 40th (I) or 50th 
(II,III) section throughout the brains was stained for microtubule-associated 
protein-2 (MAP-2) and the MAP-2 area outlined and measured (Micro Image 
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version 4.0 Olympus). Infarct area was assessed as the MAP-2 negative area 
in the ipsilateral hemisphere, tissue loss was calculated by subtracting the 
MAP-2 positive volume of the ipsilateral hemisphere from the contralateral 
hemisphere and atrophy was calculated by subtracting the MAP-2 positive 
volume and infarct volume of the ipsilateral hemisphere from the 
contralateral hemisphere. Total infarct, atrophy and tissue loss volume, was 
calculated according to the Cavalieri Principle using the following formula: 
V = ΣA x P x T, where V = total volume, ΣA = the sum of areas measured, P 
= the inverse of the sections sampling fraction, and T = the section thickness. 
 
Regional neuropathology was evaluated in MAP-2-stained sections using a 
semiquantitative neuropathological scoring system (II). Briefly, cortical 
injury was graded from 0 to 4, 0 being no observable injury and 4 being 
confluent infarction encompassing most of the hemisphere. Damage in the 
hippocampus, striatum, and thalamus was assessed both with respect to 
hypotrophy (shrinkage; grades 0–3) and observable cell injury/infarction 
(grades 0–3) resulting in a neuropathological score for each brain region 
(grades 0–6). The total score (0 –22) was the sum for all four regions. 
 
Subcortical white matter injury was analyzed by measuring the area (Micro 
Image version 4.0, Olympus) of positive staining for myelin basic protein 
(MBP) in both hemispheres at striatum and hippocampal levels (II,III). One 
section for each level was analyzed per animal. The MBP area in the 
ipsilateral hemisphere was compared with the contralateral hemisphere to 
calculate the proportion (%) of white matter damage. 
 
Comment: MAP-2 is a commonly used marker for evaluation of tissue loss 
after brain injury [189]. MAP-2 is expressed in neurons and dendrites, and 
the loss of MAP-2 staining indicates neuronal death. MBP is a protein, which 
is a constituent of the myelin sheath of oligodendrocytes and is also believed 
to be important in the process of myelination of neurons. Loss of MBP can be 
an indicator of disruption in the myelination process or reduced myelin [190, 
191]. 
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3.7 Reverse transcription-quantitative PCR 
Analyses of mRNA expression were performed with RT-qPCR. QuantiTect 
Reverse Transcription Kit (Qiagen, Sweden)(III, IV) or Superscript RNase H- 
reverse transcriptase kit (Invitrogen, CA, USA) random hexamer primers and 
dNTP (Roche Molecular Biochemicals, USA) (I) was used to synthesize first 
strand complementary DNA (cDNA) according to the manufacturer’s 
instructions. Each PCR (20 μl) contained 2 μl cDNA diluted 1:4, 10 μl 
Quanti Fast SYBR Green PCR Master Mix (Qiagen, Sweden), 2 μl PCR 
primer, and 6 μl H20. The amplification protocol comprised an initial 5 min 
denaturation at 95°C, followed by 40 cycles of denaturation for 10 sec at 
95°C and annealing/extension for 30 sec at 60°C on a LightCycler 480 
(Roche, Sweden). Melting curve analysis was performed to ensure that only 
one PCR product was obtained. For quantification and for estimating 
amplification efficiency, a standard curve was generated using increasing 
concentrations of cDNA. The amplification transcripts were quantified with 
the relative standard curve and normalized against reference genes.  
 
Table 2. Primers used with RT-qPCR. All from Qiagen, Sweden 
Gene Product number Paper 
CD31 QT01052044 IV 
Claudin-1 QT00159278 IV 
Claudin-5 QT00254905 IV 
Fas QT00095333 III 
GAPDH QT01658692 III 
Hprt-1 QT00166768 I 
IFN-β QT00249662 III 
IL-1β QT01048355 III 
IL-6 QT00098875 III 
IL-10 QT00106169 III 
IP-10 QT00093436 III 
MCP-1 QT00167832 III 
Occludin QT00111055 IV 
TLR 1 QT00157430 I 
TLR 2 QT00129752 I 
TLR 3 QT00122983 IV 
TLR 4 QT00259042 IV 
TNF-α QT00104006 III 
YWHAZ QT00105350 III 
ZO-1 QT00493899 IV 
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In paper I, we also analyzed gene expression with the RT2-PCR-Profiler PCR 
Array for TLR signaling pathways. cDNA-synthesis was performed by using 
the RT2 First Strand Kit (SABiosciences, USA) following the manufacturer’s 
instructions. The mouse TLR signaling pathway RT2-PCR-Profiler PCR 
Array (SABiosciences, USA) was carried out according to manufacturer’s 
instructions using the LightCycler 480 system (Roche, Sweden). The raw 
data obtained from the Lightcycler 480 software was uploaded into GEarray 
Analyzer software (SABiosciences, USA) for analysis. 
 
Comment: RT-qPCR is a good method to use for quantification of specific 
mRNA transcripts within a sample. RT-qPCR has an advantage over 
traditional PCR in that the kinetics of the reaction for every cycle can be 
monitored and data collection in the exponential phase of the PCR is 
possible. The choice of reference genes is important when you do a relative 
quantification. A reference gene should be constitutively expressed and not 
change due to treatments or time points within an experiment. The reference 
genes provide an internal control for variability in RNA loading and the 
efficiency of the PCR. The reference genes in this thesis were selected either 
from reference genes used in the RT2-PCR-Profiler PCR Array (I) or from 
genes suggested after evaluation with the Mouse Endogenous Control Gene 
Panel (TATAA Biocenter) (III, IV). 
3.8 Cytokine assay (II) 
Cytokine-chemokine expression in brain homogenate supernatants from WT 
and MyD88 KO mice were performed using a Linco Research mouse 22-Plex 
kit (No. MCYTO-70K-PMX22; Millipore) containing premixed beads 
capable of detecting a variety of cytokines, according to the manufacturer’s 
instructions. This microbead array allowed for the simultaneous detection of 
multiple inflammatory molecules in a single 75 µl brain homogenate sample, 
as previously described [192]. Results were analyzed on a Bio-Plex 
workstation (Bio-Rad) and normalized to the amount of protein per well. The 
level of sensitivity for each microbead cytokine standard curve ranged from 1 
to 35 pg/ml [192]. Protein concentrations were determined using the Bio-Rad 
DC Protein Assay (Bio-Rad). 
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3.9 Isolation of the blood and CSF brain barrier 
(IV) 
Choroid plexus 
Animals were deeply anesthetized and decapitated. Brains were rapidly 
dissected out and placed in a petri dish with PBS. Choroid plexus  from the 
lateral ventricles were dissected out under a microscope, snap frozen and 
stored at -80°C until analysis. 
Microvessel endothelial cells 
Endothelial cells and small vessels were isolated by microvessel isolation. 25 
µl of sheep anti rabbit magnetic beads (Dynabeads® M-280 Sheep anti-
Rabbit IgG, 112.03D, Invitrogen), resuspended in Hank’s balanced salt 
solution (HBSS, 14025-050, Invitrogen), were incubated with 5 µl of rabbit 
anti-human CD31 antibody (ab32456, Abcam) at 4°C over night.  
Animals were deeply anesthetized and decapitated. Brains were rapidly 
dissected out and placed in ice cold HBSS for ~10 min. Brains were diced 
into ~1 mm3 cubes and placed in 1 ml HBSS with 10µl collagenase/dispase 
(10269638001, Roche) at 37°C for 30-45 min. Every 15 min, the cell 
suspension was drawn through needles with decreasing bore size (21G and 
23G). The cell suspension was centrifuged for 7 min at 1000 g and washed 
three times in HBSS and then resuspended in the antibody-magnetic bead 
solution prepared from the day before and incubated for 30 min at 4°C. After 
incubation, the tubes containing cell suspension and magnetic beads were 
placed in a magnetic tube rack where beads and bound cells adhere to the 
side of the tube and remaining cell suspension could be removed. The bead 
and cell mix were washed 5 times in cold HBSS and then retained as the 
endothelial cell enriched fraction until analysis.  
Comment: The purity of the isolation product was controlled by examining 
the mRNA expression of CD31 in the endothelial cell enriched fraction 
compared to brain homogenate sample. The efficiency of the isolation 
method has previously been examined by FACS analyses with a high yield of 
CD 31 positive cells and high purity (97%) as a result (M Evans, H Stolp- 
Personal communication).  
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3.10 Statistics 
In paper I, Brain infarct data were analyzed with one way ANOVA followed 
by Dunnett’s Multiple Comparison Test to compare total infarct volume 
between genotypes or infarct area at each brain level between groups (WT, 
TLR 1 KO and TLR 2 KO). Data are presented as mean ± SD. Gene array 
data were analyzed with GEarray Analyzer software (SABiosciences, USA).  
 
In paper II, data were analyzed by two-way ANOVA with genotype (WT or 
MyD88 KO) and treatment (vehicle or LPS) as factors followed by the 
Bonferroni post hoc test with a 95% confidence interval.  
 
In paper III, brain injury and IFN-β expression data were analyzed with two-
way ANOVA with genotype and treatment or treatment and time point as 
factors followed by Bonferroni post hoc test with a 95% confidence interval. 
The other gene expression data were analyzed with one-way ANOVA 
followed by Bonferroni post hoc test with a 95% confidence interval. WT and 
TRIF KO data were analyzed separately.  
 
In paper IV, gene expression data were analyzed with Students t-test or one 
way ANOVA followed by Dunnett’s Multiple Comparison Test. 
 
Data are presented as mean ± SEM and significance was set at p≤ 0.05. All 
statistical analyses were performed using GraphPad Prism (GraphPad 
Software).  
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4 SUMMARY OF RESULTS 
4.1 TLR are expressed under normal 
conditions and after HI in the immature 
brain (I) 
Gene expression 
PND 9 mice were subjected to HI and sacrificed at 30 min, 6 h and 24 h post-
HI and gene expression analysis for TLR 1-9 was performed with the RT2-
PCR-Profiler array. mRNA for TLR 1-9 was found expressed both in normal 
brain and after HI. Additionally, we found that HI affects the separate TLRs 
differently (paper I, Table 1). TLR 1 mRNA expression showed both down-
regulation (30 min, p = 0.004) and up-regulation (6 h and 24 h, p = 0.00001). 
TLR 2 was up-regulated at both 6 and 24 h (p = 0.005, p = 0.006, 
respectively) and mRNA expression of TLR 7 was up-regulated at 24 h (p = 
0.005). Down-regulation only was found with TLR 5 at 24 h (p = 0.004) and 
TLR 8 at 30 min (p = 0.006). The gene expression of TLR 3, 4, 6, and 9 did 
not change after HI. 
Protein expression and distribution in the brain 
To further study TLR regulation following injury, we performed 
immunohistochemical studies of the TLRs that displayed significant up-
regulation of mRNA in response to HI, i.e. for TLR 1 and 2. We did also 
perform IHC with antibodies against TLR 3, 4, 5, 7, 8, and 9 but the resulting 
staining was negative or unspecific and not further analyzed. There was no 
TLR 1 positive cells detected in normal control brains or in the contralateral 
(non-damaged) hemisphere following HI. At 24 h after HI, TLR 1 positive 
cells were found expressed in the ipsilateral (damaged) hemisphere, mainly in 
hippocampus. These cells were later identified as neurons (paper I, figure 2 
and 3). TLR 2 positive astrocytes were observed mainly in the hippocampus, 
subcortical white matter and stria terminalis. TLR 2 was also shown to be 
expressed in a specific population of neurons in the paraventricular nucleus 
(PVN) of hypothalamus (paper I, figure 2 and 4). The immunohistochemical 
expression of TLR 2 did not change after HI. 
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4.2 TLRs are expressed and regulated in the 
BBB and BCSFB of the immature brain (IV) 
The BBB and the BCSFB protect the CNS from the changeable environment 
of the blood stream and control the transport of molecules into the CNS. 
Inflammatory conditions can lead to disturbed barrier function and therefore, 
we wanted to examine the expression of TLRs in choroid plexus and 
endothelial cells and how they are regulated after inflammatory stimuli with 
different TLR ligands.  
 
WT mice were given ligands for TLR 1/2 (Pam), TLR 3 (Poly I:C) or TLR 4 
(LPS) at PND 8 and were then sacrificed 14 h later. Choroid plexus and brain 
endothelial cells were isolated and the gene expression for TLR 1-4 was 
examined with RT-qPCR. All TLRs investigated were expressed both in 
choroid plexus and endothelial cells under normal (saline) conditions (paper 
IV, figure 2). In choroid plexus, stimuli with Pam resulted in an increased 
mRNA expression of TLR 1 and 2 and a decreased expression of TLR4. Poly 
I:C increased specifically the expression of TLR 3. Interestingly, LPS did not 
affect TLR 4 mRNA expression but increased the expression of TLR 1 and 
TLR 3.  
 
In endothelial cells, a similar expression pattern was observed with an 
increased expression of TLR 1 and TLR 2 after Pam exposure and increased 
expression of TLR 3 after Poly I:C (paper IV, figure 3). Similar to that 
observed in the choroid plexus, LPS did not affect TLR 4 expression in 
endothelial cells. In contrast to the choroid plexus, LPS induced an increased 
TLR 2 expression in the endothelial cells. 
 
To evaluate barrier properties after stimuli with TLR ligands, we examined 
mRNA expression for the tight junction proteins claudin-1, claudin-5, 
occludin and ZO-1. In choroid plexus, occludin was down regulated after 
both Pam and LPS stimuli. No differences were observed in the expression of 
the other tight junction proteins after administration of the different TLR 
ligands. In brain endothelial cells, there were no differences in expression in 
any of the tight junction proteins investigated. 
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4.3 TLR signaling pathways are involved in HI 
injury (I-III) 
To further evaluate the role of TLRs in neonatal HI, we performed studies 
with transgenic mice lacking functional TLR 1, TLR 2, MyD88 or TRIF. 
MyD88 and TRIF are the two main adaptor proteins downstream of the 
TLRs. After HI, TLR 2 KO mice had a significantly smaller infarct volume 
(p = 0.005), whereas no protection was observed in the TLR 1, MyD88 or 
TRIF KO mice compared to WT mice (paper I-III). These data confirm 
reports in adult animals [179, 180].   
 
LPS sensitizes the brain to HI via signaling through TLR 4 [169, 173] and 
this leads to bigger injuries than with HI alone. In paper II, we demonstrate 
an increased tissue loss in LPS pretreated WT mice after HI compared to HI 
only (p ≤ 0.001) (paper II, figure 1). Similarly, evaluation of regional 
neuropathology showed that brain injury was significantly increased in LPS-
pretreated WT mice by 112% in the cortex, 76% in the thalamus, 62% in the 
striatum, and 51% in the hippocampus. There was also a significant increase 
in loss of subcortical white matter after HI in LPS treated WT mice compared 
to HI alone (p ≤ 0.05) (paper II, figure 2). In the MyD88 KO mice, no 
differences were seen between LPS pretreated mice and HI alone, neither in 
grey matter nor in white matter injury. Two-way ANOVA revealed a 
significant interaction between genotype and treatment for both grey matter 
(p < 0.006) and white matter (p = 0.0077). Our results are in agreement with 
previous findings that LPS pre-exposure sensitizes the neonatal brain to HI 
injury [169] and we show here that LPS sensitization of the neonatal brain to 
HI is regulated in a MyD88-dependent manner.  
TRIF is the adaptor protein downstream of TLR 3 and TLR 4. Stimulation of 
the TRIF pathway via activation of TLR 4 has been shown to protect the 
adult brain from subsequent ischemic injury via TRIF-induced IFN-β [181]. 
In paper III, we examined whether or not activation of the TRIF pathway 
affects neonatal HI brain injury. The combination of Poly I:C administration 
and HI, with a 14 h interval between the two events, were performed in WT 
and TRIF KO neonatal mice and neuropathology was examined 5 days after 
HI. In WT mice, Poly I:C pretreated mice showed an increased infarct 
volume (p ≤ 0.001), tissue loss (p ≤ 0.001), and atrophy (p ≤ 0.01) compared 
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to control mice (saline/HI) (paper III, figure 2). Poly I:C pretreatment did 
also increase subcortical white matter loss both at hippocampal level (p ≤ 
0.001) as well as striatum level (p ≤ 0.001) (paper III, figure 3). The 
sensitizing effect of Poly I:C was blocked in TRIF KO mice both in grey 
matter and white matter. These results show that pre-activation of the TRIF 
pathway, mediated by Poly I:C, sensitizes the immature brain to a subsequent 
ischemic injury.  
 
4.4 Inflammation responses after TLR stimuli (II 
and III) 
As mentioned above, cytokines and chemokines are upregulated in the brain 
after a variety of insults, including stroke and inflammation. In an attempt to 
understand the sensitizing effect LPS and Poly I:C have on the brain we 
examined the role of MyD88 and TRIF in mediating inflammatory mediators 
after systemic administration of LPS or Poly I:C. 
Inflammatory response after LPS (II) 
LPS was administered to WT or MyD88 KO mice and the animals were 
sacrificed at 2, 6, and 14 h after LPS. The production of inflammatory 
mediators in the brain was examined using multiplex ELISA and the results 
were broadly divided into proinflammatory and anti-inflammatory cytokines, 
and chemokines-chemotaxic molecules.  In WT mice, significant changes 
were seen in the proinflammatory cytokines IL-1α, IL-5, IL-6, IL-7, and 
TNF-α (paper II, figure 4). The LPS induced increases in these cytokines 
were largely inhibited in the MyD88 KO animals. No significant interaction 
or genotype-dependent differences in response to LPS was seen for the 
proinflammatory cytokines IL-15 and IL-17 and the anti-inflammatory 
cytokines IL-9, IL-10, and IL-13 (paper II, figure 4 and 5). The chemokines-
chemotaxic molecules IP-10, macrophage inflammatory protein (MIP)-1α, 
granulocyte colony-stimulating factor (G-CSF), KC (also called chemokine 
(C-X-C motif) ligand 1), and MCP-1 showed similar expression patterns as 
the proinflammatory cytokines with a significant interaction with genotype 
and time (paper II, figure 6). Also here, the response was inhibited in the 
MyD88 KO mice. 
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Inflammatory response after Poly I:C (III) 
Poly I:C or saline was administered to WT and TRIF KO mice and the 
animals were sacrificed at 6 and 14 h after Poly I:C. Genes associated with 
proinflammatory and anti-inflammatory immune responses and chemotaxis 
were analyzed with RT-qPCR. All proinflammatory (IL-1β, IL-6, TNF-α), 
and chemotaxic genes (MCP-1, IP-10) investigated, as well as the anti-viral 
molecule IFN-β were upregulated in the WT mice at 6 h and/or 14 h after 
Poly I:C (paper III, figure 1 and 5). The gene expression of the anti-
inflammatory cytokine IL-10 was below detection limit in both WT and 
TRIF KO mice. No changes were seen between treatment groups in the TRIF 
KO mice.  
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5 DISCUSSION 
Infection/inflammation and/or HI are major causes of perinatal brain injury. 
TLRs are important components of the innate immunity and have been 
shown to be involved in brain injury in the adult, both after infectious and 
endogenous, non-infectious, stimuli. In this thesis we have studied the 
expression of TLRs in the immature brain and their role following neonatal 
inflammation and/or HI.   
5.1 TLR expression in the immature brain 
We demonstrated the presence of TLR 1-9 mRNA in the normal neonatal 
brain under physiological conditions. Additionally, the presence of TLR 1-4 
mRNA was shown in brain endothelial cells and choroid plexus. Similarly, 
studies in human cerebral tissue have indicated that most of the TLRs are 
expressed on the mRNA level in numerous cell types [155]. In vitro studies 
also indicate a broad expression of TLR mRNA in several neural cell types 
[154, 193-195], although the expression of neuronal TLR mRNA is more 
controversial [196]. The presence of TLRs has also been demonstrated on rat 
cerebral endothelial cells [197]. To our knowledge, this is the first report 
showing TLR mRNA expression in the choroid plexus of the perinatal brain. 
Further it is the first general characterization of TLR gene response in the 
neonatal brain after HI. 
 
After inflammatory stimuli or HI, the gene expression of several TLRs was 
changed. The regulation of TLR genes after inflammatory stimuli or neonatal 
HI is consistent with several studies in the adult brain. Previous studies have 
shown a changed TLR expression in rat cerebral endothelial cells after 
inflammatory stimuli with TNF-α and by oxidative stress [197] and an 
increased expression of TLR 2 and TLR 3 has been demonstrated on 
endothelial cells after stimuli with Pam and Poly I:C [198, 199]. After 
ischemia, studies have shown up-regulation of TLR 2 mRNA expression 
after middle cerebral artery occlusion (MCAO) [178], and induction of TLR 
2, 4, and 9 mRNA after focal ischemia in mice [200]. Also, in a model of 
spinal cord injury, there was an increased mRNA expression of TLR 1, 2, 4, 
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5, and 7 [201]. This is to some extent similar to our results indicating an 
increase of TLR 1, 2, and 7 after HI. However, in contrast to studies in adult 
rodents, we found reduced mRNA expression of TLR 5 (24 h after HI) and 
TLR 8 (30 min after HI). We did not find changes in TLR 3, 4, 6 and 9 after 
neonatal HI, which suggests that the TLR response to cerebral ischemia 
differs in the adult compared to the developing brain.  
 
We found a specific up-regulation of TLR 1, 2 and 3 in both choroid plexus 
and endothelial cells after stimulation with each of the respective ligands 
(Pam and Poly I:C). The TLR 4 mRNA expression however, did not change 
after LPS administration. TLR 4 mRNA has been found to be expressed in 
the CNS, particularly in choroid plexus [196]. Our results confirm the 
presence of TLR 4 mRNA in these CNS structures, but may indicate that 
LPS-induced TLR 4 activation does not necessarily involve TLR 4 regulation 
on a gene expression level. Similarly, we have previously noted a lack of 
TLR 4 gene expression regulation in the CNS in response to LPS in neonatal 
rats [169]. Interestingly, TLR 4 mRNA was reduced in choroid plexus 
following Pam administration. This suggests that there may be interactions 
between the TLR 2 and TLR 4 receptors, which have also previously been 
reported in the adult brain [202]. We also found an up-regulation of TLR 1 
and TLR 3 in the choroid plexus after LPS. TLR 3 was found up-regulated 
after LPS exposure in human peripheral blood monocytes and this up-
regulation appears to be positively regulated by a TLR 4-MyD88-NF-κB 
dependent signaling pathway [203]. Whether this could be true also for the 
LPS regulated TLR 1 and 3 mRNA expressions in choroid plexus needs to be 
further investigated. 
 
In addition to TLR gene expression, we also investigated protein expression 
of the TLRs that was most regulated following HI, i.e. TLR 1 and TLR 2. We 
found an increase of TLR 1 positive neurons in the injured hemisphere after 
HI. To our knowledge, there are no previous studies of TLR 1 expression 
after ischemic injury, either in the adult or developing brain. In an adult 
model of neurocysticercosis, TLR 1 expression has been demonstrated on 
infiltrating cells such as microglia/macrophages[154]. These differences in 
expression may be due to age-and/or injury- dependent factors.  
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TLR 2 was constitutively expressed in the neonatal brain and the expression 
did not change with HI. Thus, the pattern of protein expression after HI 
differed to some extent to the mRNA expression. This kind of differences 
between gene expression and protein expression have previously been 
reported [154] suggesting that TLRs may be posttranscriptionally regulated.  
 
TLR 2 was expressed in white matter astrocytes as well as in a specific 
population of neurons in PVN. Our results goes well with previous studies 
where TLR 2 expression has been detected in microglia, neurons, ependymal 
cells and astrocytes, [154] and a constitutive expression of TLR 2 has been 
demonstrated by in situ hybridization specifically in stria terminalis, PVN, 
and in the supraoptic nucleus [204]. The function of the TLR 2 positive 
neurons in PVN is to our knowledge unknown. PVN consists of several 
subpopulations of neurons involved in neuroendocrine function, such as 
homeostatic control, by releasing corticotropin-releasing hormone (CRH) and 
vasopressin. In close proximity to the PVN, there are specific structures, 
usually referred to as circumventricular organs (CVOs), which are lacking 
BBB (reviewed in [205]). CVOs are localized at strategic points close to the 
midline of the brain within the ependymal walls lining the 3rd and the 4th 
ventricle. Because of their fenestrated endothelial cells, they lie within the 
blood milieu and thus form a blood-CSF barrier. CVOs play a role in 
neurochemical and neurosecretory functions, in that the neurons located in 
the CVOs can directly sense hormonal stimuli and other substances in the 
blood or secrete hormones into the blood. Previous studies have shown that 
CVOs are the site of entry for immune cells into the CNS and CSF during 
inflammatory circumstances [206], and inflammatory stimuli, such as LPS 
and IL-1β, are known to activate secretory neurons in PVN [207-209]. Based 
on these results, we speculate that the TLR 2 positive neurons in the PVN 
that we found in paper I may participate in the neuroendocrine response of 
the hypothalamus and may act as sensors for incoming inflammatory signals. 
5.2 TLRs and brain injury 
In paper I, we examined the role of TLR 1 and TLR 2 in neonatal hypoxic-
ischemic brain damage. Even though there was an increased TLR 1 
expression in injured areas of the brain after HI, lack of TLR 1, in TLR 1 
deficient mice, did not protect from HI injury. As far as we are aware, this is 
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the first study that has investigated the role of TLR 1 in HI brain damage. In 
contrast, TLR 2 expression did not change after HI, but we found that TLR 2 
deficiency protected the immature brain from HI damage. With respect to 
TLR 2, our results correspond well with previous reports in adult animals. 
The majority of existing studies have shown a damaging [195, 200, 210] role 
for TLR 2 in the ischemic injured brain, although one study has reported that 
TLR 2 deficient mice develop larger infarcts following acute cerebral 
ischemia/reperfusion injury [204]. Furthermore, intracerebral administration 
of the TLR 1/2 agonist Pam caused brain damage, which was prevented in 
TLR2 KO mice [211]. In support we have previously shown that repeated 
stimulation of the TLR 2 receptor during early neonatal development results 
in brain injury and this effect is blocked in TLR 2 deficient mice [174].  
 
Several TLR 2-dependent functions in CNS have been described, both in the 
normal healthy situation and after injury. Cerebral cortical neurons up-
regulate TLR 2 in response to ischemia/reperfusion injury and an increased 
number of apoptotic neurons are found in the murine dentate gyrus 24 h after 
stimulation with a TLR 2 agonist [195, 211]. TLR 2 has also been found to 
be involved in adult hippocampal neurogenesis [212] and after a spinal cord 
injury, TLR 2 is important for the regulation of inflammation and gliosis as 
well as the repair and functional recovery [201]. Thus, it appears that TLR 2 
signaling is emerging as a critical component of CNS function, both in health 
and disease. 
 
All TLRs, except TLR 3, use the adaptor protein MyD88 for intracellular 
signaling. TLR 3 signaling is dependent on the adaptor protein TRIF, while 
both MyD88 and TRIF are associated with TLR 4 signaling. In paper II and 
III, we investigated the role of the adaptor proteins MyD88 and TRIF in HI 
injury. Neither MyD88 KO, nor TRIF KO mice were protected following HI 
alone. This coincides well with previous findings in adult mice [179, 180]. 
MyD88 is believed to be the sole adaptor protein downstream of TLR 2. The 
lack of protection in MyD88 KO mice (Paper II), while TLR 2 KO mice 
demonstrated reduced infarct area following HI (Paper I), may seem 
contradictory but suggest that TLR 2 may play a role in neonatal ischemic 
injury, independent of MyD88. A differential effect in MyD88 KO and TLR 
2/4 KO mice following brain damage has also been shown in the adult [213]. 
How MyD88 is involved in other TLR 2-dependent functions in CNS, or 
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whether TLR 2 may also have additional/alternative downstream signaling 
pathways, is still not known.  
 
We further investigated the role of the adaptor proteins MyD88 and TRIF by 
combining specific stimulation of either TLR 3 (Poly I:C) or TLR 4 (LPS) 
with a HI insult. We show that MyD88 plays an essential role in LPS-
sensitized HI brain injury since MyD88 KO mice were protected against the 
combined LPS and HI effect (Paper II). These results support our previous 
findings identifying LPS as an important factor in altering the vulnerability to 
HI injury in the neonate [169-172] and provide novel evidence that the 
sensitizing effect of LPS is mediated via MyD88. This is the first report 
identifying a role for MyD88 regulation in LPS-induced HI brain injury.  
 
We also show that pretreatment with the TLR 3 agonist Poly I:C sensitizes 
the neonatal brain to subsequent HI through a TRIF-dependent pathway 
(Paper III). In contrast, activation of the TRIF pathway has been shown to be 
protective against ischemic injury in the adult [181]. This effect was 
mediated via TRIF/IRF3-induced IFN-β. We could not detect such a 
relationship in our studies, despite showing a marked increase in IFN-β 
following Poly I:C administration. However, in support of our studies, it has 
also been shown that Poly I:C exacerbates the inflammatory response and 
accelerates neurodegeneration in the adult brain [182] and increases the 
susceptibility of midbrain dopaminergic neurons to subsequent neurotoxicity 
[214]. Furthermore, maternal immune challenges with Poly I:C precipitates 
neurodevelopmental diseases later in life in rodents [215]. Taken together, 
our data suggests that activation of TLR 3/TRIF by Poly I:C is detrimental to 
the neonatal brain. 
5.3 Inflammatory response after TLR stimuli 
and/or HI 
We have previously shown that peripheral LPS exposure regulates the 
expression of a large number of genes in the neonatal brain [116], including a 
significant number associated with inflammatory processes, such as 
cytokines and chemokines. We report in paper II and III that exposure to LPS 
or Poly I:C increase mainly proinflammatory cytokine and chemokine levels 
in the brain whereas there were no significant changes in anti-inflammatory 
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cytokines. The proinflammatory response to LPS and Poly I:C was largely 
abolished in MyD88 KO mice and TRIF KO mice respectively. These results 
are supported by previous studies, both in vitro[192, 216, 217] and in vivo 
[111, 182, 218, 219].  
It is known that systemic inflammation can damage the brain through 
induction of inflammatory mediators, such as cytokines (reviewed in [220]). 
Additionally, proinflammatory cytokines cause damage if injected directly 
into the brain [89] and have the capacity to exacerbate brain damage [221], 
whereas blocking proinflammatory cytokine production by gene deletion 
reduces brain damage [66, 222, 223].  
We do not know whether the cytokines in the brain after LPS or Poly I:C are 
produced locally by resident microglia in the brain or produced by infiltrating 
cells. LPS, when systemically administered, induce a systemic production of 
cytokines in blood borne cells, which can increase the permeability of the 
BBB and thereby permit inflammatory mediators to access the brain 
(reviewed in [224]). LPS itself does not appear to cross the BBB but instead 
bind to endothelial cells of the brain [225] and to areas of the brain lacking 
BBB [226] and thereby inducing a CNS response, mainly through activation 
of microglia. Resident microglia, and not infiltrating cells, have been found 
to be the main macrophage type activated in the brain after ischemic injury 
[227] and this suggests that resident microglia may be the main source of 
cytokine production in the brain also after systemic inflammation. In support, 
in studies in adult animals, it was shown that non-hematopoietic cells are 
critical for the CNS inflammation following systemic LPS exposure. This 
effect was not dependent on cytokine production in the blood [196]. Further 
studies are needed to investigate if Poly I:C works in the same way. 
Both MCP-1 and IL-1β are known to be able to exacerbate neonatal 
excitotoxic lesions [221, 228]) and deletion of the entire TNF gene cluster 
abolishes LPS-mediated increase in neonatal HI injury [229], suggesting that 
these cytokines may play a role in inflammatory-induced neonatal brain 
damage. The direct influence of IL-6 on the development of brain injury is 
more unclear. Although studies have consistently demonstrated elevated IL-6 
levels in asphyxiated infants [95] and mice overexpressing IL-6 develop 
severe neurologic syndromes [96], others find that mice deficient in IL-6 
develop more severe brain injuries [97].  
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Although there was an early increase in proinflammatory cytokines and 
chemokines in WT mice after LPS exposure, the inflammatory response was 
more or less resolved at 14 h, the time point when HI was induced. A similar 
response was seen for IL-6 and IP-10 after Poly I:C exposure, whereas MCP-
1 expression was still high, and IL-1β, TNF-α expression was even further 
increased at 14 h. It is unclear to what extent the inflammatory response 
contributed to the increased vulnerability of the brain to HI. It was previously 
shown that cell medium from LPS stimulated microglia cells can kill both 
neurons [230] and astrocytes [231] and at least neuronal death was dependent 
on MyD88.  
Both MAPK and NF-κB play important roles in the proinflammatory 
response. IL-6, IL-1β, TNF-α, and MCP-1 are all regulated by the 
transcription factor NF-κB [118-122] after inflammatory stimuli. It has also 
been shown that Poly I:C gives rise to an induction of IFN-β, TNF-α and IP-
10 in vivo and that the activation of NF-κB and the MAPKs JNK and ERK 
are required for the TLR 3 induced IP-10 gene expression [114]. Studies have 
also shown that NF-κB activation of IL-6 occurs through MAPKs [232]. 
Additionally, we, and others have previously shown that MAPKs are 
involved in neonatal HI [233-235] and inhibition of NF-κB activity attenuates 
HI brain injury in neonatal mice, independent of cytokine production [236, 
237]. Recently, we also demonstrated that inhibition of p38 MAPK blocks 
cytotoxic effects of LPS-stimulated microglia on astrocytes [231]. MAPKs 
and NF-κB seems to be closely related and therefore, it could be useful to not 
only focus on the end product of the inflammatory response, but rather 
investigate the molecules upstream of the proinflammatory cytokines to 
explore future treatment strategies. 
5.4 TLRs and barriers of the brain 
The BBB and the choroid plexus have been suggested to be the site of entry 
of inflammatory mediators into the CNS during systemic inflammation. 
Furthermore, in response to LPS, the barrier permeability and genes 
regulating barrier maintenance and inflammatory cascades are affected both 
in BBB and in the blood-CSF barrier [136-139]. It is shown in this thesis that 
activation of TLR 3 with Poly I:C (paper III) or TLR 4 with LPS (paper II) 
sensitizes the immature brain to HI  injury and we have previously shown 
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that systemic stimulation of TLR 2 impairs neonatal mouse brain 
development [174].  
 
In order to test whether stimulation of TLRs leads to changes in brain barrier 
properties in the immature brain, we investigated the gene expression of 
several tight junction proteins in brain endothelial cells and choroid plexus 
(paper IV). Tight-junctions are made up of a range of proteins where occludin 
and claudins are transmembrane components and ZO-1 is one of the principal 
anchoring proteins of occludin inside the cell membrane. The claudins differ 
somewhat between tight junctions throughout the body and claudin-5 is 
believed to be the principal claudin in brain endothelial cells. Claudin-1 is 
found together with claudin-2 and claudin-11 in the epithelial cells of choroid 
plexus [238].  
 
In BBB endothelial cells, we found that there was little regulation of tight 
junction proteins by any of the TLR ligands. However, in epithelial cells of 
the choroid plexus there was a significant down-regulation of occludin both 
after Pam and LPS exposure. Others have shown that activation of the TLR 
2/6 complex lead to increased BBB permeability through downregulation of 
claudin-5 and occludin [197]. Furthermore, it has been shown that specific 
stimulation of TLR 2 or TLR 3 impair endothelial function by increased 
endothelial permeability, increased production of inflammatory cytokines and 
reactive oxygen species, and increased apoptosis of ECs [198, 199]. The 
exact molecular function of the different tight junction proteins and how they 
interact is still under debate. Studies of claudin-5 knock-out animals have 
shown that it can have a direct effect on blood-brain barrier permeability 
[239]. There are also several studies showing that changes to barrier 
permeability often is associated with alterations of both occludin and ZO-1 
[240-242]. Our data suggest a possible mechanism where systemic 
stimulation of TLRs in the neonate may lead to disturbances in choroid 
plexus barrier function that may affect CNS injury at later stages. Future 
studies should investigate the functional barrier properties after TLR 
stimulation in neonatal animals to better understand these relationships. 
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6 CONCLUSIONS OF THE MAIN FINDINGS 
IN THE THESIS 
 TLRs are expressed under basal conditions in the immature brain in 
numerous cell types in the brain parenchyma as well as in choroid 
plexus and blood brain barrier, suggesting that they may play 
essential roles in normal neurophysiological processes. Several of the 
TLRs are also regulated in the brain, choroid plexus and blood brain 
barrier after HI. Stimulation of TLR 1/2 (Pam) or TLR 4 (LPS) 
decreased the mRNA expression of the tight junction protein 
occludin in choroid plexus. These results suggest a role for TLRs in 
neuropathology and that TLRs may not only be involved in 
parenchymal inflammation, but may also play a role in transport 
across the blood and cerebral spinal fluid barriers. 
 
 TLR 2 contributes to brain damage after HI alone, indicating that it 
has a role in sterile inflammation in the neonatal brain. In contrast, 
the adaptor proteins MyD88 and TRIF do not appear to play a role in 
the injury process after HI alone. These somewhat contradictory 
results of the neuroprotective effect in MyD88 (adaptor molecule 
downstream of TLR 2) and TLR 2 deficient mice suggest that there 
may be alternative TLR 2 downstream pathways in the CNS, apart 
from MyD88. Future studies should investigate this possibility by 
studying downstream TLR 2 associated pathways in detail following 
neonatal HI.  
 
 MyD88 plays an essential role in LPS-sensitized HI brain injury; this 
support our previous findings identifying LPS as an important factor 
in altering the vulnerability to HI injury in the neonate and provide 
novel evidence that the sensitizing effect of LPS is mediated via 
MyD88. In recent years the importance of bacterial infections, 
resulting in inflammation in both preterm and term infants have been 
emphasized. This study indicates that the adaptor protein MyD88 
may be a critical component in these events. 
 
  46 
 Activation of the TRIF pathway, with Poly I:C, prior to HI markedly 
increased brain injury. The increased vulnerability to HI was 
associated with TRIF-dependent induction of both type I interferons, 
proinflammatory cytokines, and chemokines, suggesting that several 
pathways, including different transcription factors and MAPKs, are 
involved in the cerebral response to TRIF stimulation. Poly I:C  is a 
synthetic mimic of double stranded RNA viral products. Therefore, 
the Poly I:C-induced increase in vulnerability to HI may indicate that 
viral infections could impact on HI brain injury in the newborn. 
 
It is nowadays well established that infection/inflammation contributes to the 
development of perinatal brain damage in both preterm infants and full term 
children subjected to birth asphyxia (HI). These injuries can cause severe 
neurological and cognitive dysfunction, but also more subtle disturbances in 
behavior, learning and perception. The brain can probably be affected by both 
a systemic as well as local inflammation, which can influence brain 
maturation and development or modulate the brain's vulnerability to other 
insults. However, the inflammatory response is complex and may also have 
neuroprotective properties. Today there is a lack of treatment for perinatal 
brain damage and of satisfactory knowledge of underlying mechanisms and 
how therapies may affect the immune system. The current thesis has 
demonstrated that TLRs are involved in immature brain injury, both after 
infection- and HI-induced inflammation, or a combination of them both. Thus 
TLRs may provide novel targets for neuroprotective therapies in the future.  
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